AIMC Topic: Androgen Antagonists

Clear Filters Showing 11 to 18 of 18 articles

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology Dec 20, 2017
Purpose We evaluated the relationship between prostate-specific antigen (PSA) and overall survival in the context of a prospectively randomized clinical trial comparing androgen-deprivation therapy (ADT) plus docetaxel with ADT alone for initial meta...
Kallikreins Adult Neoplasms, Hormone-Dependent Male Middle Aged Time Factors Prostate-Specific Antigen Humans Androgen Antagonists Databases, Factual Docetaxel Neoplasm Metastasis Antineoplastic Combined Chemotherapy Protocols Retrospective Studies Treatment Outcome Aged Randomized Controlled Trials as Topic Aged, 80 and over Prostatic Neoplasms
View on PubMed DOI

Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.

International journal of radiation oncology, biology, physics Nov 8, 2016
PURPOSE: NRG Oncology RTOG 9202 was a randomized trial testing long-term adjuvant androgen deprivation (LTAD) versus initial androgen deprivation only (STAD) with external beam radiation therapy (RT) in mostly high-risk and some intermediate-risk pro...
Male Middle Aged Time Factors Treatment Outcome Adenocarcinoma Prostatic Neoplasms Prostate-Specific Antigen Neoplasm Grading Retrospective Studies Aged Aged, 80 and over Survival Rate Humans Antineoplastic Agents, Hormonal Radiotherapy, Conformal Drug Administration Schedule Androgen Antagonists Risk Combined Modality Therapy Kaplan-Meier Estimate Disease-Free Survival
View on PubMed DOI

Sentinel Lymph Node Dissection to Select Clinically Node-negative Prostate Cancer Patients for Pelvic Radiation Therapy: Effect on Biochemical Recurrence and Systemic Progression.

International journal of radiation oncology, biology, physics Oct 19, 2016
PURPOSE: To assess the efficacy of robotic-assisted laparoscopic sentinel lymph node (SLN) dissection (SLND) to select those patients with prostate cancer (PCa) who would benefit from additional pelvic external beam radiation therapy and long-term an...
Patient Selection Radiotherapy, Conformal Statistics, Nonparametric Sentinel Lymph Node Biopsy Lymphatic Irradiation Robotic Surgical Procedures Pelvis Androgen Antagonists Neoplasm Recurrence, Local Prostatic Neoplasms Neoplasm Staging Prostate-Specific Antigen Humans Aged Male Middle Aged Disease Progression Nomograms Lymphatic Metastasis
View on PubMed DOI

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.

Clinical genitourinary cancer Dec 17, 2015
INTRODUCTION: We evaluated the incidence and predictors of the use of long-term (2-3 years) versus shorter term androgen deprivation therapy (ADT) in radiation-managed men with high-risk prostate cancer.
Neoplasm Grading Tertiary Care Centers Humans Androgen Antagonists Male Practice Patterns, Physicians' Treatment Outcome Regression Analysis Drug Administration Schedule Prostatic Neoplasms Prostate-Specific Antigen
View on PubMed DOI

Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series.

Journal of medical imaging and radiation oncology Jan 15, 2015
INTRODUCTION: We compare the results of modern external-beam radiotherapy (EBRT), using combined androgen deprivation and dose-escalated intensity-modulated radiotherapy with MRI-CT fusion and daily image guidance with fiducial markers (DE-IG-IMRT), ...
Aged Aged, 80 and over Survival Rate Male Humans Retrospective Studies Risk Factors Androgen Antagonists Disease-Free Survival Radiotherapy, Conformal Brachytherapy Chemoradiotherapy Australia Middle Aged Robotics Prevalence Prostatic Neoplasms Treatment Outcome Surgery, Computer-Assisted
View on PubMed DOI

Pilot study of an artificial intelligence-based deep learning algorithm to predict time to castration-resistant prostate cancer for metastatic hormone-naïve prostate cancer.

Japanese journal of clinical oncology Sep 18, 2022
The object in this study is to develop an artificial intelligence-based deep learning algorithm for prediction of time to castration-resistant prostate cancer by combined androgen blockade therapy in metastatic hormone-naïve prostate cancer. We inclu...
Pilot Projects Androgen Antagonists Prostatic Neoplasms, Castration-Resistant Androgens Humans Artificial Intelligence Male Deep Learning
View on PubMed DOI

Low Risk of Venous Thromboembolism After Robot-assisted Radical Prostatectomy Through Systemic Image Assessment: A Prospective Study.

In vivo (Athens, Greece) Jan 1, 2022
BACKGROUND/AIM: The aim of the study was to evaluate the risk of venous thromboembolism (VTE) after robot-assisted radical prostatectomy (RARP) and discuss whether a uniform prophylaxis for VTE after radical prostatectomy is also suitable for robotic...
Androgen Antagonists Venous Thromboembolism Lymphocele Prostatectomy Male Humans Urinary Bladder Neoplasms Prospective Studies Robotics Risk Factors Prostatic Neoplasms
View on PubMed DOI

[Downregulation of PTTG1 expression inhibits the proliferation and invasiveness and promotes the apoptosis of human prostate cancer LNCaP-AI cells].

Zhonghua nan ke xue = National journal of andrology Jul 1, 2017
OBJECTIVE: To investigate the effects of down-regulation of PTTG1 expression on the proliferation, invasiveness and apoptosis of androgen-independent human prostate cancer LNCaP-AI cells and their sensitivity to androgen antagonists.
Prostatic Neoplasms Androgen Antagonists RNA, Small Interfering Transfection Humans Securin Cell Line, Tumor Down-Regulation Male Cell Proliferation Time Factors Apoptosis Neoplasm Invasiveness
View on PubMed
Popular Topics
Recent Journals